Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., . . . Greenhalf, W. (2021). hENT1 predicts benefit from gemcitabine in pancreatic cancer but only with low CDA mRNA. Cancers, 13(22), . https://doi.org/10.3390/cancers13225758
Chicago-Zitierstil (17. Ausg.)Aughton, Karen, et al. "HENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA MRNA." Cancers 13, no. 22 (2021). https://doi.org/10.3390/cancers13225758.
MLA-Zitierstil (9. Ausg.)Aughton, Karen, et al. "HENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA MRNA." Cancers, vol. 13, no. 22, 2021, https://doi.org/10.3390/cancers13225758.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.